Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
View/ Open
Date
2019-02-01ICR Author
Author
Bancroft, EK
Saya, S
Page, EC
Myhill, K
Thomas, S
Pope, J
Chamberlain, A
Hart, R
Glover, W
Cook, J
Rosario, DJ
Helfand, BT
Hutten Selkirk, C
Davidson, R
Longmuir, M
Eccles, DM
Gadea, N
Brewer, C
Barwell, J
Salinas, M
Greenhalgh, L
Tischkowitz, M
Henderson, A
Evans, DG
Buys, SS
IMPACT Study Steering Committee,
IMPACT Collaborators,
Eeles, RA
Aaronson, NK
Type
Journal Article
Metadata
Show full item recordAbstract
OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36-item short-form health survey (SF-36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale-Revised, risk perception and knowledge. The results of the baseline questionnaire are presented. RESULTS: A total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants' perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF-36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status. CONCLUSION: This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer-specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening.
Subject
IMPACT Study Steering Committee
IMPACT Collaborators
Humans
Prostatic Neoplasms
Risk Factors
Case-Control Studies
Longitudinal Studies
Health Knowledge, Attitudes, Practice
Depression
Anxiety
Perception
Psychiatric Status Rating Scales
Mutation
Genes, BRCA1
Genes, BRCA2
Quality of Life
Adult
Middle Aged
Male
Early Detection of Cancer
Surveys and Questionnaires
Research team
Clinical Academic Radiotherapy (Dearnaley)
Oncogenetics
Stereotactic and Precision Body Radiotherapy
Language
eng
Date accepted
2018-05-21
License start date
2019-02
Citation
BJU international, 2019, 123 (2), pp. 284 - 292
Publisher
WILEY
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0
Related items
Showing items related by title, author, creator and subject.
-
The impact of 2D cine MR imaging parameters on automated tumor and organ localization for MR-guided real-time adaptive radiotherapy.
Menten, MJ; Fast, MF; Wetscherek, A; Rank, CM; Kachelrieß, M; et al. (2018-11-22)2D cine MR imaging may be utilized to monitor rapidly moving tumors and organs-at-risk for real-time adaptive radiotherapy. This study systematically investigates the impact of geometric imaging parameters on the ability ... -
Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer
Woolston, A; Barber, L; Griffiths, B; Pich, O; Lopez-Bigas, N; et al.Anti-EGFR antibodies such as cetuximab are active against KRAS/NRAS wild-type colorectal cancers (CRC) but acquired resistance invariably evolves. Which mutational mechanisms enable resistance evolution and whether adaptive ... -
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
Vaclova, T; Grazini, U; Ward, L; O'Neill, D; Markovets, A; et al. (2021-03-19)Advanced non-small-cell lung cancer (NSCLC) patients with EGFR T790M-positive tumours benefit from osimertinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Here we show that the size of the ...